Home Nav
Nextech Invest Logo

Lutz Kummer

Alfred Scheidegger

Lutz most recently served as Associate Director of Research at Sosei Heptares, an international biopharmaceutical group deploying structure-based drug design and proprietary approaches for engineering of functional, stabilized G protein-coupled receptors (GPCRs). Prior to his role at Sosei Heptares, Lutz served as the CSO and co-founder of G7 Therapeutics, where he led the company's overall R&D strategy and work-flow leading up to the recent $12M acquisition of G7 by Heptares Therapeutics. Lutz holds a PhD in Biochemistry and Molecular Life Sciences from the University of Zurich and worked closely with Andreas Plückthun during his PhD studies, publishing in the fields of protein biochemistry, engineering of biologics, and small molecule ligand discovery.


Personalized Oncology 2019 conference

23.06. – 25.06.2019

Basel, Switzerland

  • 24.07.2019

    Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives...

  • 18.07.2019

    Blueprint Medicines Announces European Medicines Agency...

  • 15.07.2019

    Neon Therapeutics ’ Personal Neoantigen Vaccine Study...


Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.


* Compulsory fields


Newsletter Registration

Your eMail have been successfully registered.